Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug 30;12(8):1830-1833.
doi: 10.21037/tlcr-23-271. Epub 2023 Jul 19.

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer

Hao Chen  1 , Kentaro Yumoto  2 , Fumihiro Kashizaki  2 , Harumi Koizumi  2 , Ichiro Ikeda  1 , Nobuyuki Horita  3 , Kenichi Takahashi  2 , Takeshi Kaneko  4
Affiliations
Editorial

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer

Hao Chen et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Chemotherapy; KEYNOTE-407; immune checkpoint inhibitor (ICI); non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-271/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Novello S, Kowalski DM, Luft A, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol 2023;41:1999-2006. 10.1200/JCO.22.01990 - DOI - PMC - PubMed
    1. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018;379:2040-51. 10.1056/NEJMoa1810865 - DOI - PubMed
    1. Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 2023;41:1992-8. 10.1200/JCO.22.01989 - DOI - PMC - PubMed
    1. Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol 2020;15:1351-60. 10.1016/j.jtho.2020.03.028 - DOI - PubMed
    1. Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol 2023;41:1200-12. 10.1200/JCO.22.01503 - DOI - PMC - PubMed